1. Silverstein, M.D., Heit, J.A., Mohr, D.N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 1998, 158, p. 585-593.
2. Lilienfeld, D.E. Decreasing mortality from pulmonary embolism in the United States, 1979-1996. Int. J. Epidemiol. 2000, 29, p. 465-469.
3. White, R.H. The epidemiology of venous thromboembolism. Circulation 2003, 107, p. I4-I8.
4. Kahn, S.R., Ginsberg, J.S. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch. Intern. Med. 2004, 164, p. 17-26.
5. Schulman, S., Lindmarker, P., Holmstrom, M. et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J. Thromb. Haemost. 2006, 4, p. 734-742.
6. Prandoni, P., Lensing, A.W., Cogo, A. et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 1996, 125, p. 1-7.
7. Heit, J.A., Mohr, D.N., Silverstein, M.D. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 2000, 160, p. 761-768.
8. Prandoni, P., Villalta, S., Bagatella, P. et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997, 82, p. 423-428.
9. Pesavento, R., Bernardi, E., Concolato, A. et al. Postthrombotic syndrome. Semin Thromb. Hemost. 2006, 32, p. 744-751.
10. Douketis, J.D., Gu, C.S., Schulman, S. et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann. Intern. Med. 2007, 147, p. 766-774.
11. Pengo, V., Lensing, A.W., Prins, M.H. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 2004, 350, p. 2257-2264.
12. Cushman, M., Tsai, A., White, R. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am. J. Med. 2004, 117, p. 19-25.
13. Palareti, G., Legnani, C., Lee, A. et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb. Haemost. 2000, 84, p. 805-810.
14. Schulman, S., Svenungsson, E., Granqvist, S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 1998, 104, p. 332-338.
15. Hansson, P.O., Sörbo, J., Eriksson, H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 2000, 160, p. 769-774.
16. Douketis, J.D., Crowther, M.A., Foster, G.A., Ginsberg, J.S. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am. J. Med. 2001, 110, p. 515-519.
17. Boutitie, F., Schulman, S., Kearon, C. et al. Factors at baseline influencing the risk of recurrence in venous thromboembolism: results of a meta-analysis on individual patient data. Blood 2003, 102, Abstract 730.
18. McRae, S., Tran, H., Schulman, S. et al. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006, 368, p. 371-378.
19. Kyrle, P.A., Minar, E., Bialonczyk, C. et al. The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. 2004, 350, p. 2558-2563.
20. Ögren, M., Eriksson, H., Bergqvist, D., Sternby, N.H. Subcutaneous fat accumulation and BMI associated with risk for pulmonary embolism in patients with proximal deep vein thrombosis: a population study based on 23 796 consecutive autopsies. J. Intern. Med. 2005, 258, p. 166-171.
21. Schulman, S., Wåhlander, K., Lundström, T. et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran (THRIVE III). N. Engl. J. Med. 2003, 349, p. 1713-1721.
22. Christiansen, S.C., Cannegieter, S.C., Koster, T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005, 293, p. 2352-2361.
23. Ho, W.K., Hankey, G.J., Quinlan, D.J., Eikelboom, J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch. Intern. Med. 2006, 166, p. 729-736.
24. Marchiori, A., Mosena, L., Prins, M.H., Prandoni, P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007, 92, p. 1107-1114.
25. Ageno, W., Becattini, C., Brighton, T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008, 117, p. 93-102.
26. Heit, J.A., Silverstein, M.D., Mohr, D.N. et al. The epidemiology of venous thromboembolism in the community. Thromb. Haemost. 2001, 86, p. 452-463.
27. Eichinger, S., Hron, G., Bialonczyk, C. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Intern. Med. 2008, 168, p. 1678-1683.
28. Prandoni, P., Lensing, A.W., Prins, M.H. et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann. Intern. Med. 2002, 137, p. 955-960.
29. Hron, G., Kollars, M., Binder, B.R. et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006, 296, p. 397-402.
30. Bounameaux, H., Perrier, A. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am. Soc. Hematol. Educ. Program. 2008, p. 252-258.
31. Levine, M.N., Raskob, G., Beyth, R.J. et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126, p. 287S-310S.
32. Linkins, L.A., Choi, P.T., Douketis, J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann. Intern. Med. 2003, 139, p. 893-900.
33. Ruíz-Gimínez, N., Suárez, C., González, R. et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb. Haemost. 2008, 100, p. 26-31.
34. Garcia, D. Novel anticoagulants and the future of anticoagulation. Thromb. Res. 2009, 123,Suppl. 4, p. S50-S55.
35. Nishioka, J., Goodin, S. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J. Oncol. Pharm. Pract. 2007, 13, p. 85-97.
36. Spinler, S.A., Wittkowsky, A.K., Nutescu, E.A., Smythe, M.A. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann. Pharmacother. 2005, 39, p. 1275-1285.
37. Louzada, M.L., Majeed, H., Wells, P.S. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb. Res. 2009, 123, p. 837-844.
38. Nishio, H., Ieko, M., Nakabayashi, T. New therapeutic option for thromboembolism−dabigatran etexilate. Expert. Opin. Pharmacother. 2008, 9, p. 2509-2517.
39. Schulman, S., Kearon, C., Kakkar, A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009, 361, p. 2342-2352.
40. Raghavan, N., Frost, C.E., Yu, Z. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug. Metab. Dispos. 2009, 37, p. 74-81.
41. AMPLIFY - EXT. A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism [on-line]. Dostupné na http://clinicaltrials.gov/ct2/show/NCT00633893.
42. Weinz, C., Schwarz, T., Kubitza, D. et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug. Metab. Dispos. 2009, 37, p. 1056-1064.
43. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 2010, 363, p. 2499-2510